Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Defactinib

    Client Email Product

    Defactinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    21
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone
    Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone

    https://www.businesswire.com/news/home/20240305616374/en

    BUSINESSWIRE
    05 Mar 2024
    Share Share
    Verastem Oncology Outlines Key 2024 Strategic Priorities
    Verastem Oncology Outlines Key 2024 Strategic Priorities

    https://www.businesswire.com/news/home/20240124822477/en

    BUSINESSWIRE
    29 Jan 2024
    Share Share
    Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib
    Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib

    https://www.businesswire.com/news/home/20231213489476/en

    BUSINESSWIRE
    13 Dec 2023
    Share Share
    Verastem Oncology Announces Efficacy and Safety Data of Avutometinib
    Verastem Oncology Announces Efficacy and Safety Data of Avutometinib

    https://www.businesswire.com/news/home/20231106345111/en

    BUSINESSWIRE
    06 Nov 2023
    Share Share
    Verastem Presents Avutometinib and Defactinib Combination Program Updates
    Verastem Presents Avutometinib and Defactinib Combination Program Updates

    https://www.businesswire.com/news/home/20230928230044/en

    BUSINESSWIRE
    28 Sep 2023
    Share Share
    Verastem Oncology Announces Design for Trial of Avutometinib and Defactinib
    Verastem Oncology Announces Design for Trial of Avutometinib and Defactinib

    https://www.businesswire.com/news/home/20230705791373/en

    BUSINESSWIRE
    05 Jul 2023
    Share Share
    Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Ovarian Cancer
    Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Ovarian Cancer

    https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer

    ONCLIVE
    30 Jun 2023
    Share Share
    New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial
    New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial

    https://www.businesswire.com/news/home/20230426005206/en

    BUSINESSWIRE
    26 Apr 2023
    Share Share
    Verastem Announces Data from PII RAMP-201 Trial of Avutometinib and Defactinib
    Verastem Announces Data from PII RAMP-201 Trial of Avutometinib and Defactinib

    https://www.businesswire.com/news/home/20230123005740/en

    BUSINESSWIRE
    24 Jan 2023
    Share Share
    Verastem Oncology Reports Second Quarter 2022 Financial Results
    Verastem Oncology Reports Second Quarter 2022 Financial Results

    https://www.businesswire.com/news/home/20220808005195/en

    BUSINESS WIRE
    08 Aug 2022
    Share Share
    Verastem Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib
    Verastem Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib

    https://www.businesswire.com/news/home/20220606005303/en

    BUSINESSWIRE
    06 Jun 2022
    Share Share
    Verastem Provides Financial Update to Support Development of VS-6766, Defactinib
    Verastem Provides Financial Update to Support Development of VS-6766, Defactinib

    https://www.businesswire.com/news/home/20220328005165/en

    BUSINESSWIRE
    28 Mar 2022
    Share Share
    Verastem Presents Updated PI/II Data of VS-6766 + Defactinib in Ovarian Cancer
    Verastem Presents Updated PI/II Data of VS-6766 + Defactinib in Ovarian Cancer

    https://www.businesswire.com/news/home/20210919005021/en

    BUSINESSWIRE
    19 Sep 2021
    Share Share
    Drug combination shows promise in treatment-resistant advanced ovarian cancer
    Drug combination shows promise in treatment-resistant advanced ovarian cancer

    https://www.icr.ac.uk/news-archive/drug-combination-shows-promise-in-treatment-resistant-advanced-ovarian-cancer

    ICR
    19 Sep 2021
    Share Share
    Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766
    Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766

    https://www.businesswire.com/news/home/20201215005318/en

    BUSINESSWIRE
    15 Dec 2020
    Share Share
    Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766
    Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766

    https://www.businesswire.com/news/home/20201130005327/en

    BUSINESSWIRE
    30 Nov 2020
    Share Share
    Verastem Oncology Ph2 Registration-Directed Trial of VS-6766 and Defactinib
    Verastem Oncology Ph2 Registration-Directed Trial of VS-6766 and Defactinib

    https://www.businesswire.com/news/home/20201130005327/en/Verastem-Oncology-Initiates-Phase-2-Registration-Directed-Trial-of-VS-6766-and-Defactinib-in-Recurrent-Low-Grade-Serous-Ovarian-Cancer

    BUSINESSWIRE
    29 Nov 2020
    Share Share
    Verastem Oncology Announces of Preclinical Data Supporting the CombO of VS-6766
    Verastem Oncology Announces of Preclinical Data Supporting the CombO of VS-6766

    https://www.businesswire.com/news/home/20200622005650/en/Verastem-Oncology-Announces-Presentation-Preclinical-Data-Supporting

    BUSINESSWIRE
    22 Jun 2020
    Share Share
    Verastem Announces Presentation of Preclinical Data VS-6766 and Defactinib
    Verastem Announces Presentation of Preclinical Data VS-6766 and Defactinib

    https://www.businesswire.com/news/home/20200622005650/en

    BUSINESSWIRE
    22 Jun 2020
    Share Share
    What's in Store for Verastem (VSTM) This Earnings Season?
    What's in Store for Verastem (VSTM) This Earnings Season?

    https://www.nasdaq.com/article/whats-in-store-for-verastem-vstm-this-earnings-season-cm1046217

    NASDAQ
    30 Oct 2018
    Share Share
    Verastem Oncology to Present Scientific Data Supporting Duvelisib & Defactinib
    Verastem Oncology to Present Scientific Data Supporting Duvelisib & Defactinib

    https://www.businesswire.com/news/home/20180521006003/en

    BUSINESSWIRE
    21 May 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search